Study immune drug plus chemo before surgery versus surgery first
Treatments studied
Part of Cancer clinical trials.
This Phase 3 trial compares two treatment plans for stage III/IVA head and neck squamous cell cancer (HNSCC). One plan uses an immune drug with chemotherapy before surgery; the other goes straight to surgery first, to see which approach works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed head and neck squamous cell cancer (HNSCC) and your doctors plan curative surgery for stage III or stage IVA.
- You are 18 to 79 years old.
- Your health is good enough for treatment (ECOG performance status 0 or 1).
- You have no prior treatment with immune checkpoint drugs (such as anti–PD-1, anti–PD-L1, anti–PD-L2, or anti–CTLA-4 antibodies).
- Your blood tests, kidney function, and liver function are within required limits from recent screening labs.
- You can provide tissue samples for research (unused pre-treatment tissue and any remaining post-surgery tissue).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This Phase 2 study tests whether giving low-dose radiation before surgery—along with chemotherapy and an immunotherapy drug—can work better and be safe for treating locally advanced head and neck squamous cell cancer. It may help shrink tumors before surgery and reduce the chance of the cancer coming back.
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
This Phase 2 trial tests tirelizumab combined with two chemotherapy medicines before surgery for certain head and neck squamous cell cancers. It aims to shrink the tumor and improve outcomes after the operation.
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
Hear when a new Head and Neck Squamous Cell Carcinomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.